Roche's Avastin boosts survival of brain cancer patients

ZURICH Fri Aug 10, 2012 10:44am IST



ZURICH Aug 10 (Reuters) - Swiss drugmaker Roche Holding AG said a new study of cancer drug Avastin showed it significantly extended life expectancy of people with an aggressive form of brain cancer.

The Phase III AVAglio study met one of its main targets of improving progression-free survival in people with glioblastoma, Roche, the world's largest maker of cancer drugs, said in a statement on Friday.

"This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy," Roche said.

(Reporting by Andrew Thompson)


After wave of QE, onus shifts to leaders to boost economy

DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.